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Fairer distribution of medical
resources?
The National Department of Health has been taken to task on
several issues, among them being the incomprehensible delay on
the development of a plan to deal with HIV/AIDS, including the
provision of antiretroviral drugs, forcing the special licensing of
dispensing doctors, and the proposed Certificate of Need
(regulating where doctors may practise in future).  Taylor and Burns
(p. 180) review some of the positive aspects of recent developments
in health care with regard to changes within the medical scheme
environment.
Funding disparities include the private sector health care
spending being more than five times the per capita expenditure of
the public sector and, until recently, discrimination within the
private sector against the sick and those with lower incomes. Since
South Africa’s progressive Constitution includes the individual’s
right to access to health services, one of the government’s objectives
in health care funding reform would be to reduce inequities in
health care financing, enabling a ‘public health’ approach to
resource allocation. 
In its regulations, the Medical Schemes Act of 1998 includes open
enrolment, community-rating as opposed to risk-taking and
prescribed minimum benefits. The paper addresses several other
issues including the establishment of alternative reim-
bursement  models and prioritisation of resource allocation.
The authors conclude that legislation has enabled an environment
of fairer budget allocation within the private sector and protects
drainage of public-sector resources by medical scheme members.
For the intentions of social health reform to be realised, the health
care market must respond responsibly, there must be acceptance of
population-based prioritisation of health care resources that must be
based on sound scientific, economic and ethical thinking.  
In his editorial, Johann van Zyl (p. 170) suggests that the
solutions proposed are based largely on existing paradigms and
that increases in medical scheme contributions have been the trend.
The total insured population has decreased and the major portion of
the costs associated with health care in the private sector is still
borne by the members themselves, despite the tax subsidisation. He
considers it debatable that the introduction of prescribed minimum
benefits has decreased the burden on public sector resources.
All agree that it is critically important for all role-players,
especially practising providers of care, to participate in the debate
and influence decision-makers meaningfully.
Pentoxifylline for heart failure
Scientific and medical papers have been declining in South Africa
for some time. It is therefore encouraging that the SAMJ has been
receiving an increasing number of good student papers, such as the
systematic review on pentoxifylline by Kathryn Batchelder and
Bongani Mayosi (p. 175). Readers will also have noted the
increasing number of published systematic reviews that add to our
growing evidence-based knowledge and thereby, it is hoped, will
influence medical practice.
Heart failure, typically a progressive disease, now affects 22
million people worldwide. Despite strides in the treatment of end-
stage heart failure, these measures remain largely palliative.
Pentoxifylline has vasodilatory, anti-inflammatory and anti-
apoptotic properties that have made it a prime candidate for the
treatment of heart failure. 
The systematic review findings suggest that pentoxifylline may
be effective in improving symptoms and cardiac function in people
with heart failure due to idiopathic and ischaemic cardiomyopathy,
and that it may have a promising effect on mortality. However the
existing trials included a small number of patients, so they may not
provide reliable and robust estimates of the effect of pentoxifylline
on important outcomes such as mortality. The authors conclude
that, on the basis of the currently available evidence, pentoxifylline
cannot yet be recommended for routine use in patients with heart
failure.
Amiodarone-induced thyroid
dysfunction
Thyroid dysfunction (TD) is a common complication of amiodarone
therapy. Ross and colleagues (p. 184) report on a large analysis of
TD associated with amiodarone therapy. Amiodarone is a widely
used anti-arrhythmic drug with a considerable potential to cause
TD because of its 35% iodine content. It is generally accepted that
the frequency of hypothyroidism and hyperthyroidism is accounted
for by differing levels of iodine intake.  
Although hypothyroidism was the commonest TD in this study, it
constituted a smaller proportion than in previous studies. The
prevalence of thyrotoxicosis was 7.3%. Management of amiodarone-
induced TD is difficult and withdrawal of amiodarone may not be
possible, particularly when used for ventricular arrhythmias.
ICU tracheostomy outcomes
An unfavourable outcome of patients discharged from the
intensive care unit (ICU) is reported by Mpe and Mphahlele (p.
188). Tracheostomies are performed on ICU patients to facilitate
airway management, particularly in those who need an artificial
airway over weeks. A Glasgow Coma Scale (GCS) of 8 at discharge
is associated with increased mortality and there was a mortality of
92% in patients with a discharge GCS of less than 4.
The mortality figures, which are in excess of other published
values, may be due to the unit performing tracheostomies on
patients who have an overall poor prognosis, and the care of
tracheostomies in general wards may be inadequate. The study
also raises important moral and ethical questions of fair use of
resources in a resource-limited environment.
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